Deals and Financings   Gracell Biotech of Suzhou raised $209 million in a US IPO for its next-gen CAR-T treatments, which can be manufactured in one day or are off-the-shelf products; APT Medical staged a $191 million IPO on the Shanghai STAR Exchange, rising 245% in its first trading session, for its cardiovascular catheter devices; Shanghai 's Zai Lab acquired greater China rights to a novel argenx SE treatment for autoimmune indications in a deal worth up to $175 million; Abbisko Therapeutics of Shanghai completed a $123 million Series D financing to develop its portfolio of 12 oncology and one diabetes candidates; Advaccine Biopharma Suzhou announced a $108 million agreement to acquire Greater China rights to a DNA vaccine for COVID-19 from US-based Inovio; Terns, a San Mateo-Shanghai biopharma, completed a $87 million Series C round to support its three lead NASH programs; Boston 's Paratek Pharma closed a $60 million non-recourse loan that will be paid off by royalties paid by Zai Lab on a product it in-licensed from Paratek; Kira Pharma closed a $53.5 million Series B+ financing to develop complement-targeted therapies that treat immune-mediated diseases; Keya Medical completed a $46 million D financing in late December to support its automated scanning products based on deep learning algorithms; Shanghai 's Ocumension Therapeutics invested $15.7 million in its US partner, EyePoint Pharma of Massachusetts ; Trials and Approvals   Everest Medicines was approved to start a China Phase III trial of an ADC urothelial cancer treatment in-licensed from a Gilead company; Company News   Shanghai Pharma broke ground on a $1.8 billion, 3.2 million-square-foot park devoted to incubating novel therapeutic antibodies along with cell and gene therapies. Stock Symbols: (NSDQ: GRCL) (SHA: 688617) (NSDQ: ZLAB; HK: 9688) (Euronext & NSDQ: ARGX) (NSDQ: INO) (NSDQ: PRTK) (HK: 1477) (NSDQ: EYPT) (HK: 1952) (NSDQ: GILD) (SHA: 601607; HK: 2607) Share this with colleagues: // //